A. Fields

发表

Upstaging pathologic stage I ovarian carcinoma based on dense adhesions is not warranted: a clinicopathologic study of 84 patients originally classified as FIGO stage II.

R. Zaino, Brant G. Wang, J. Seidman, 2010, Gynecologic oncology.

A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumors.

S. Agrawal, S. Mani, S. Goel, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers

Sanjay Goel, Gary Goldberg, M. Einstein, 2005, Investigational New Drugs.

Prophylactic Surgery in Hereditary Breast/Ovarian Cancer Syndrome

N. Goldman, A. Fields, 2003 .

Survival and toxicity differences between 5‐day and weekly cisplatin in patients with locally advanced cervical cancer

Gloria S. Huang, S. Kalnicki, M. Einstein, 2007, Cancer.

Efficacy and toxicity of concomitant cisplatin with external beam pelvic radiotherapy and two high-dose-rate brachytherapy insertions for the treatment of locally advanced cervical cancer.

S. Kalnicki, M. Einstein, S. Hailpern, 2007, Gynecologic oncology.

Extended‐field radiotherapy and high–dose‐rate brachytherapy in carcinoma of the uterine cervix

B. Vikram, C. Runowicz, M. Garg, 2003, Cancer.

Two fractions of high-dose-rate brachytherapy in the management of cervix cancer: clinical experience with and without chemotherapy.

B. Vikram, C. Runowicz, M. Garg, 2002, International journal of radiation oncology, biology, physics.

Mature results of a phase II trial of concomitant cisplatin/pelvic radiotherapy for locally advanced squamous cell carcinoma of the cervix.

C. Runowicz, S. Wadler, J. Beitler, 1996, Gynecologic oncology.

Current Therapies in Ovarian Cancer

C. Runowicz, A. Fields, 2003, Cancer investigation.

Consolidation therapy for ovarian cancer

Gloria S. Huang, A. Fields, G. Goldberg, 2005 .

Impact of Chemotherapy and Radiotherapy on the Uterus

G. Priore, D. Gudipudi, A. Fields, 2012 .

Allelotype of papillary serous peritoneal carcinomas.

R. L. Baldwin, B. Karlan, H. Klinger, 2001, Gynecologic oncology.

Screening for gynecologic malignancies: A continuing responsibility.

C. Runowicz, A. Fields, 1999, Surgical oncology clinics of North America.

All‐trans retinoic acid and interferon‐α‐2a in patients with metastatic or recurrent carcinoma of the uterine cervix

S. Hallam, C. Runowicz, S. Wadler, 1997 .

All-trans retinoic acid and interferon-alpha-2a in patients with metastatic or recurrent carcinoma of the uterine cervix: clinical and pharmacokinetic studies. New York Gynecologic Oncology Group.

S. Hallam, C. Runowicz, S. Wadler, 1997, Cancer.

Profound thrombocytopenia in previously treated patients with recurrent ovarian carcinoma receiving topotecan.

C. Runowicz, I. Cass, A. Fields, 1998, Gynecologic oncology.

Induction of transforming growth factor beta-1 in cervical intraepithelial neoplasia in vivo after treatment with beta-carotene.

C. Runowicz, A. Fields, G. Goldberg, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma.

B. Vikram, C. Runowicz, C. Guha, 2003, International journal of radiation oncology, biology, physics.

Promising new therapies in the treatment of advanced ovarian cancer

C. Runowicz, A. Fields, G. Goldberg, 1995, Cancer.

Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium.

C. Runowicz, S. Wadler, A. Murgo, 2006, Gynecologic oncology.

Evaluation of low-dose intraperitoneal interferon-alpha for palliation of ascites in patients with non-ovarian gynecologic malignancies.

C. Runowicz, D. Khabele, A. Fields, 2003, Gynecologic oncology.

Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas.

B. Karlan, L. Lagasse, C. Runowicz, 2001, Gynecologic oncology.

Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC).

M. Einstein, A. Novetsky, A. Fields, 2008, Gynecologic oncology.

Continuous low-dose combined hormone replacement therapy and the risk of endometrial cancer.

C. Runowicz, A. Fields, G. Goldberg, 1997, Gynecologic oncology.

How Often Should a Port-A-Cath be Flushed?

A. Fields, G. Goldberg, J. Santiago, 2005, Cancer investigation.

PSC833: initial clinical results in refractory ovarian cancer patients.

P. Dottino, C. Runowicz, S. Wadler, 1998, Current opinion in oncology.

Pelvic exenteration for cervix cancer: would additional intraoperative interstitial brachytherapy improve survival?

C. Runowicz, S. Wadler, J. Beitler, 1997, International journal of radiation oncology, biology, physics.

The genetics of ovarian cancer: an assessment of current screening protocols and recommendations for counseling families at risk.

S. Aufox, A. Bombard, A. Fields, 1996, Clinical obstetrics and gynecology.

Colony-stimulating factor-1 and its receptor do not have a role in the pathogenesis of uterine sarcomas.

J. Pollard, C. Runowicz, A. Fields, 1999, Gynecologic oncology.

Analysis of MDR1 expression in normal and malignant endometrium by reverse transcription-polymerase chain reaction and immunohistochemistry.

C. Runowicz, S. Horwitz, J. Jones, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Altered expression of transforming growth factor‐β1 in cervical neoplasia as an early biomarker in carcinogenesis of the uterine cervix

K. Flanders, C. Runowicz, A. Fields, 1996, Cancer.

Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma.

E. Warner, G. Bjarnason, C. Cripps, 1999, Acta oncologica.

Total pelvic exenteration: the Albert Einstein College of Medicine/Montefiore Medical Center Experience (1987 to 2003).

M. Einstein, A. Fields, G. Goldberg, 2006, Gynecologic oncology.

Phase I clinical trial of parenteral hydroxyurea in combination with pelvic and para-aortic external radiation and brachytherapy for patients with advanced squamous cell cancer of the uterine cervix.

B. Vikram, C. Runowicz, S. Wadler, 2002, International journal of radiation oncology, biology, physics.

Compliance with Papanicolaou smear screening following tubal ligation in women with cervical cancer.

C. Runowicz, A. Fields, G. Goldberg, 1999, Journal of women's health.

Long-term follow-up of stage I cervical adenocarcinoma treated by radical surgery.

J. Woodruff, G. Heatley, R. Mclellan, 1994, Gynecologic oncology.

Expression of retinoic acid receptor-beta 2 mRNA in normal cervical epithelium and cervical squamous cell carcinoma.

S. Hallam, C. Runowicz, S. Wadler, 1997, International journal of oncology.

Ovarian carcinoid: management of primary and recurrent tumors.

K. Whitney, A. Fields, G. Goldberg, 2000, Gynecologic oncology.

Preliminary phase II clinical and pharmacokinetic study of 9-cis retinoic acid in advanced cervical cancer. New York Gynecologic Oncology Group.

C. Runowicz, S. Wadler, E. Schwartz, 1999, The cancer journal from Scientific American.

The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix.

C. Runowicz, S. Wadler, J. Beitler, 1996, Seminars in oncology.

BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.

D. Fishman, B. Karlan, J. Brunet, 2000, American journal of human genetics.

Guidelines for the prevention and management of vicarious trauma among researchers of sexual and intimate partner violence

Y. Sikweyiya, J. Coles, Lusajo J. Kajula, 2015 .